The role of interleukin-6 in rheumatoid arthritis;Il ruolo dell'interleuchina-6 nell'artrite reumatoide

Recenti Progressi in Medicina

Volumn 99, Issue 6, 2008, Pages 291-294

  Manfredi, Mariangela ^a   Benucci, Maurizio ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Interleukin 6; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; INFECTION; INFLAMMATION; JOINT DESTRUCTION; MONOTHERAPY; PATHOGENESIS; RANDOMIZATION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYMPTOMATOLOGY; SYNOVIOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS; INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 46449124543     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-11.
2. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
3. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-6.
4. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
5. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-6.
6. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 11: 619-26.
7. Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993; 13: 45-51.
8. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-4.
9. Pawlik A, Wrzesniewska J, Florczak M, Gawronska-Szklarz B, Herczynska M. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005 ; 34: 109-13.
10. Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002; 196: 979-90.
11. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461-8.
12. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-50.
13. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30: 1426-35.
14. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-9.
15. Maini RN, Taylor PC, Pavelka K. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with incomplete response to methotrexate (CHARISMA). Arthritis Rheum 2003; suppl: S652.
16. Nishimoto N. Blocking interleukin-6 (IL-6) by tocilizumab (a humanized anti interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis: evidence from X-ray reader blinded randomised controlled trial. Arthritis Rheum 2005; suppl S52
17. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.